Source: https://www.nysenate.gov/legislation/bills/2019/s5935
Timestamp: 2019-08-19 11:53:34
Document Index: 595617644

Matched Legal Cases: ['§365', '§273', '§ 2', '§ 3', '§  4', '§  3']

NY State Senate Bill S5935A
senate Bill S5935A
Relates to medication assisted treatment for substance use disorders
Get Status Alerts for S5935A
Jun 19, 2019 ordered to third reading rules cal.456
substituted for a7246b
Jun 14, 2019 amended on third reading 5935a
Jun 12, 2019 referred to ways and means
Jun 04, 2019 ordered to third reading cal.1170
May 16, 2019 referred to health
S5935A
S5935 - Details
A7246
Amd §§365-a & 364-j, Soc Serv L; amd §273, Pub Health L
S5935 - Summary
Relates to medication assisted treatment for substance abuse disorders; prohibits prior authorization.
S5935 - Sponsor Memo
BILL NUMBER: S5935
TITLE OF BILL:  An act to amend the social services law and the public
health law, in relation to medication for the treatment of substance use
This legislation will expand access to medications that treat substance
Section 1 amends subdivision 2 of section 365-a of the social services
law by adding a new paragraph (gg)
Section 2 amends subdivision 26-b of section 364-j of the social
services law. Section 3 amends subdivision 10 of section 273 of the
public health law. Section 4 sets the effective date.
Medication assisted treatment, or MAT, is an evidence based treatment
method that uses FDA approved medications to help an individual overcome
a substance use disorder.Medications such as methadone, buprenorphine
and naltrexone have all been used successfully and more treatment
providers are turning to this approach given its ability to reduce and
block cravings, ease withdrawal symptoms and otherwise enable an indi-
vidual to reach recovery more easily.
However, medications used in MAT programs are not interchangeable and
each patient may respond differently, therefore it is imperative that
this choice be left to the patient and their doctor to determine the
appropriate medication. Under current law, individuals under Medicaid
are not given the opportunity to access all forms of medication assisted
treatment and may be limited to one specific type. This legislation
would allow individuals under Medicaid the ability to access whichever
MAT medication is most beneficial to them and their needs, without
utilization control, mandated prior authorization, or lifetime limits.
This act shall take effect on July 1, 2019.
S5935 - Bill Text download pdf
relation to medication for the treatment of substance use disorders
Section 1. Subdivision 2 of section 365-a of the social  services  law
is amended by adding a new paragraph (gg) to read as follows:
(GG)  ALL UNITED STATES FOOD AND DRUG ADMINISTRATION APPROVED FORMS OF
MEDICATION ASSISTED TREATMENT PRESCRIBED ACCORDING TO GENERALLY ACCEPTED
NATIONAL PROFESSIONAL GUIDELINES FOR THE TREATMENT OF  A  SUBSTANCE  USE
DISORDER.    SUCH  MEDICATION ASSISTED TREATMENT SHALL NOT BE SUBJECT TO
ANY PRIOR AUTHORIZATION MANDATE.
§ 2. Subdivision 26-b of section 364-j of the social services law,  as
added  by  section  4  of  part  B of chapter 69 of the laws of 2016, is
26-b. Managed care providers shall not require prior authorization for
[an initial or renewal  prescription  for  buprenorphine  or  injectable
naltrexone   for  detoxification  or  maintenance  treatment  of  opioid
addiction unless the prescription is for a non-preferred  or  non-formu-
lary  form of the drug or as otherwise required by section 1927(k)(6) of
the Social Security Act] ANY UNITED STATES FOOD AND DRUG  ADMINISTRATION
APPROVED  FORMS OF MEDICATION ASSISTED TREATMENT PRESCRIBED ACCORDING TO
GENERALLY ACCEPTED NATIONAL PROFESSIONAL GUIDELINES FOR THE TREATMENT OF
§ 3. Subdivision 10 of section 273 of the public health law, as  added
by  section 5 of part B of chapter 69 of the laws of 2016, is amended to
10. Prior authorization shall not  be  required  for  [an  initial  or
renewal  prescription  for  buprenorphine  or  injectable naltrexone for
detoxification or maintenance treatment of opioid addiction  unless  the
LBD10713-04-9
S. 5935                             2
prescription  is  for a non-preferred or non-formulary form of such drug
as otherwise required by section 1927(k)(6) of the Social Security  Act]
ANY UNITED STATES FOOD AND DRUG ADMINISTRATION APPROVED FORMS OF MEDICA-
TION  ASSISTED  TREATMENT  PRESCRIBED  ACCORDING  TO  GENERALLY ACCEPTED
§  4. This act shall take effect July 1, 2019; provided, however, that
the amendments to subdivision  26-b  of  section  364-j  of  the  social
services law made by section two of this act shall not affect the repeal
of such section, and shall be deemed repealed therewith.
S5935A (ACTIVE) - Details
S5935A (ACTIVE) - Summary
S5935A (ACTIVE) - Sponsor Memo
BILL NUMBER: S5935A
Section one amends subdivision 2 of section 365-a of the social services
Section two amends subdivision 26-b of section 364-j of the social
Section three amends subdivision 10 of section 273 of the public health
Section four sets the effective date.
a substance use disorder. Medications such as methadone, buprenorphine
treatment and may be limited to one specific type.  This legislation
S5935A (ACTIVE) - Bill Text download pdf
5935--A
Cal. No. 1170
Introduced by Sens. HARCKHAM, BIAGGI, CARLUCCI, KAPLAN -- read twice and
Health -- committee discharged and said bill committed to the  Commit-
tee  on  Rules -- reported favorably from said committee, ordered to a
(GG)  ALL  BUPRENORPHINE PRODUCTS, METHADONE OR LONG ACTING INJECTABLE
NALTREXONE FOR DETOXIFICATION OR MAINTENANCE TREATMENT  OF  A  SUBSTANCE
USE DISORDER PRESCRIBED ACCORDING TO GENERALLY ACCEPTED NATIONAL PROFES-
SIONAL  GUIDELINES  FOR THE TREATMENT OF A SUBSTANCE USE DISORDER.  SUCH
MEDICATION ASSISTED TREATMENT SHALL NOT BE SUBJECT TO ANY PRIOR AUTHORI-
ZATION MANDATE.
the Social Security Act] ANY BUPRENORPHINE PRODUCTS, METHADONE  OR  LONG
ACTING INJECTABLE NALTREXONE FOR DETOXIFICATION OR MAINTENANCE TREATMENT
OF  A  SUBSTANCE USE DISORDER PRESCRIBED ACCORDING TO GENERALLY ACCEPTED
LBD10713-06-9
S. 5935--A                          2
§  3. Subdivision 10 of section 273 of the public health law, as added
by section 5 of part B of chapter 69 of the laws of 2016, is amended  to
10.  Prior  authorization  shall  not  be  required for [an initial or
renewal prescription for  buprenorphine  or  injectable  naltrexone  for
detoxification  or  maintenance treatment of opioid addiction unless the
prescription is for a non-preferred or non-formulary form of  such  drug
as  otherwise required by section 1927(k)(6) of the Social Security Act]
ANY BUPRENORPHINE PRODUCTS, METHADONE OR LONG ACTING INJECTABLE NALTREX-
ONE FOR DETOXIFICATION OR  MAINTENANCE  TREATMENT  OF  A  SUBSTANCE  USE
DISORDER  PRESCRIBED  ACCORDING  TO  GENERALLY ACCEPTED NATIONAL PROFES-
SIONAL GUIDELINES FOR THE TREATMENT OF A SUBSTANCE USE DISORDER.
have become a law; provided, however, that the amendments to subdivision
26-b  of section 364-j of the social services law made by section two of
this act shall not affect the repeal  of  such  section,  and  shall  be